EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Intranasal Naloxone During Recurrent Exercise in Individuals with Type‐1 Diabetes Mellitus: Evaluation of the Clinical Predictors of Pharmacokinetics and Exposure–Response

Omar N Al Yacoub iD, Shen Cheng iD, Mohamed S Fayed, James Fisher, Jillian Brooks, Elizabeth Seaquist, Anjali Kumar, Amir Moheet, Lynn Eberly, Lisa D Coles

The Journal of Clinical Pharmacology · 2025

DOI: 10.1002/jcph.70067 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Pharmacology, 2025. Verfasst von Omar N Al Yacoub und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA. Hauptthemen laut MEDLINE: Naloxone, Diabetes Mellitus, Type 1, Narcotic Antagonists, Exercise. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Breakthrough T1D, JDRF.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Impaired awareness of hypoglycemia (IAH) impacts 25%‐30% of individuals with type 1 diabetes mellitus (T1D), potentially leading to severe outcomes due to reduced symptom perception. Naloxone, a mu‐opioid receptor antagonist, shows promise as a preventive measure against IAH. This study explored intranasal (IN) naloxone as a potential therapy to preserve counterregulatory and symptom responses to hypoglycemia following exercise in T1D patients. Participants included adults with T1D for 2‐20 years. The study aimed to develop a population pharmacokinetic (PopPK) model of IN naloxone and assess exposure–response relationships. The study was conducted as a single‐center, single‐blinded, placebo‐controlled crossover study. It involved collecting blood samples at 12 intervals before, during, and after exercise. Plasma naloxone concentrations were analyzed using high‐performance liquid chromatography‐tandem mass spectrometry (HPLC‐MS/MS). Utilizing nonlinear mixed effects modeling, the PopPK model simulated individual naloxone maximum concentrations (C max ) and total area under the curve (AUC) to evaluate exposure–response relationships. A two‐compartment model with combined zero‐ and first‐order absorption best described the naloxone's pharmacokinetics. Allometric scaling based on weight was applied to volume and clearance parameters, with a combined additive and proportional error model describing residual unexplained variability. Clearance and volume estimates were: central: 6.82 L/min/70 kg and 171 L/70 kg, peripheral: 2.97 L/h/70 kg and 278 L/70 kg. The absorption rate constant and zero‐order absorption duration were 0.0272 min −1 and 7.33 min, respectively. While a strong correlation was observed between simulated exposures (C max and AUC), no statistically significant correlation was found between exposures and responses. This is the first PopPK model of IN naloxone in T1D offering insights for future clinical pharmacokinetic studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NaloxoneDiabetes Mellitus, Type 1Narcotic AntagonistsExerciseHumansAdministration, IntranasalMaleAdultCross-Over StudiesFemaleYoung AdultModels, BiologicalSingle-Blind MethodHypoglycemiaMiddle AgedAdolescentArea Under Curve

Stichwörter der Autor:innen

PopPKexposure–responsehypoglycemianaloxonepharmacokineticstype 1 diabetes mellitus

Substanzen

NaloxoneNarcotic Antagonists

Autor:innen und Institutionen

  • Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA.
  • Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
  • Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA.

ORCID-Profile: Omar N Al Yacoub, Shen Cheng

Förderung

  • Breakthrough T1D
  • JDRF

Zitieren

APA

Al Yacoub, O. N., Cheng, S., Fayed, M. S., Fisher, J., Brooks, J., Seaquist, E., Kumar, A., Moheet, A., Eberly, L., & Coles, L. D. (2025). Intranasal Naloxone During Recurrent Exercise in Individuals with Type‐1 Diabetes Mellitus: Evaluation of the Clinical Predictors of Pharmacokinetics and Exposure–Response. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.70067

Vancouver

Al Yacoub ON, Cheng S, Fayed MS, Fisher J, Brooks J, Seaquist E, et al. Intranasal Naloxone During Recurrent Exercise in Individuals with Type‐1 Diabetes Mellitus: Evaluation of the Clinical Predictors of Pharmacokinetics and Exposure–Response. The Journal of Clinical Pharmacology. 2025. doi:10.1002/jcph.70067

BibTeX
@article{AlYacoub2025,
  author = {Al Yacoub, Omar N and Cheng, Shen and Fayed, Mohamed S and Fisher, James and Brooks, Jillian and Seaquist, Elizabeth and Kumar, Anjali and Moheet, Amir and Eberly, Lynn and Coles, Lisa D},
  title = {Intranasal Naloxone During Recurrent Exercise in Individuals with Type‐1 Diabetes Mellitus: Evaluation of the Clinical Predictors of Pharmacokinetics and Exposure–Response},
  journal = {The Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1002/jcph.70067}
}
Kostenlos starten →